个人简介：

Shirley Liu, PhD Chief Executive Officer Co-Founder Dr. Xiaole Shirley Liu co-founded GV20 Therapeutics in 2016 and became the CEO of GV20 in 2022. She was a Professor of Biostatistics and Computational Biology at Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health and co-director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute. Her computational biology work refined our understanding of hormone receptor therapies, epigenetic inhibitors, gamma-secretase inhibitors, receptor tyrosine kinase inhibitors, and immune checkpoint inhibitors in different cancers. Dr. Liu is a highly cited researcher with a prodigious publication record that includes more than 200 papers published by her group, many in high-profile journals and highly cited. Shirley received the Sloan Research Fellowship (2008), has been a Breast Cancer Research Foundation Investigator (2017) and became a Fellow of ISCB (2019). In addition, she was recognized with the Benjamin Franklin Award for Open Access in the Life Sciences and the ISCB Innovator Award in 2020. Recently, she was selected by the American Institute for Medical and Biological Engineering (AIMBE) to its 2022 College of Fellows.

公司简介：

寻百会生物科技（GV20 Oncotherapy），是一家致力于癌症精准医疗的原研新药开发企业。在肿瘤功能基因组学、癌症免疫治疗和生物大数据技术上具有国际领先的优势，并已建立了中国首个基于功能基因组学的肿瘤新药靶标筛选平台。寻百会将平台技术应用于解决肿瘤新药开发的关键问题，即鉴定有效的肿瘤药物靶标、优化联合用药组合和提高药物临床试验效果。

公司官网：http://www.bioxbh.com/